Bayer

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

India’s Supreme Court rejects patent plea by Novartis for the cancer drug Glivec

By Jeanette Jakobsson | Posted on April 18, 2013

For years, India did not offer any patent protection for chemical compounds, but was obliged to do this after joining the World Trade Organization. In 2005, the patent protection act therefore was amended to also include such compounds, but only if they proved significant clinical efficacy enhancements over already patented compounds, Section 3(d) of the Indian...

Tags: Bayer, Glivec, Novartis, Roche

Recent contributors

Ai-Leen Lim, Partner and Attorney at Law, Hong Kong SAR

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President

Julia Wang, Senior Associate and Attorney at Law, Beijing, China

Julia Wang

Senior Associate, Attorney at Law

Ylva Strandberg, Counsel and AU and NZ Patent Attorney, Stockholm, Sweden

Ylva Strandberg

Counsel, AU and NZ Patent Attorney

Hongyue Li, Senior Associate and China Patent Attorney, Beijing, China

Hongyue Li

Senior Associate, China Patent Attorney

Isa Böttiger, Associate and Attorney at Law, Stockholm, Sweden

Isa Böttiger

Senior Associate, Attorney at Law

Ylva Wikmark, Counsel and European Patent Attorney, Stockholm, Sweden

Ylva Wikmark

Counsel, European Patent Attorney